Runt-related transcription factor 1 (RUNX1) is a wellknown master regulator of hematopoietic lineages but its mechanisms of action are still not fully understood. Here, we found that RUNX1 localizes on active chromatin together with Far Upstream Binding Protein 1 (FUBP1) in human B-cell precursor lymphoblasts, and that both factors interact in the same transcriptional regulatory complex. RUNX1 and FUBP1 chromatin localization identified c-KIT as a common target gene. We characterized two regulatory regions, at +700 bp and +30 kb within the first intron of c-KIT, bound by both RUNX1 and FUBP1, and that present active histone marks. Based on these regions, we proposed a novel FUBP1 FUSElike DNA-binding sequence on the +30 kb enhancer. We demonstrated that FUBP1 and RUNX1 cooperate for the regulation of the expression of the oncogene c-KIT. Notably, upregulation of c-KIT expression by FUBP1 and RUNX1 promotes cell proliferation and renders cells more resistant to the c-KIT inhibitor imatinib mesylate, a common therapeutic drug. These results reveal a new mechanism of action of RUNX1 that implicates FUBP1, as a facilitator, to trigger transcriptional regulation of c-KIT and to regulate cell proliferation. Deregulation of this regulatory mechanism may explain some oncogenic function of RUNX1 and FUBP1.
INTRODUCTION
Hematopoiesis is an intricate process leading to the differentiation of stem cells into all hematopoietic lineages. It requires an elaborate network of transcription factors articulated with transcriptional regulators, and deregulation of those networks is implicated in hematologic malignancies. Runt-related transcription factor 1 (RUNX1) is one of these critical transcription factors playing a prominent role in hematopoiesis (1, 2) . RUNX1 is essential for definitive hematopoiesis in early development and adulthood, for megakaryocyte maturation, T-and B-cell lineages and neuronal development (3) (4) (5) (6) (7) (8) (9) (10) . In line with its founding role, loss-or gain-of-function variants of RUNX1 protein promote hematologic malignancies, notably in the most frequent pediatric subtype of leukemia, the pre-B cell acute lymphoblastic leukemia (ALL) (1) .
RUNX1 functioning is complex and remains a matter of debate. RUNX1 acts as a transcriptional platform recruiting co-factors that modulate its transcriptional activity. RUNX1 thereby endorses activator or repressor functions (11, 12) . Transcriptional activation by RUNX1 requires its Nucleic Acids Research, 2018, Vol. 46, No. 21 11215 heterodimerization with Core Binding Factor Beta (CBFB) (13, 14) and the recruitment of co-factors (CBP, P300, etc.), which display a lineage-specific or ubiquitous expression pattern, to direct specific biological programs (12, 15) . Pre-B ALL emerge from pro-B or pre-B lymphocytes where RUNX1 is essential for survival and development of B cell-specified progenitors and for the transition through the pre-B-cell stage (16) . To increase our understanding about the molecular mechanisms that modulate the transcriptional activity of RUNX1 in pre-B cells and its physiological consequences, we aimed at identifying its specific partners. Using an unsupervised approach termed RIME (rapid immunoprecipitation mass spectrometry of endogenous proteins), we identified Far Upstream Element Binding Protein 1 (FUBP1), an ATP-dependent DNA helicase and a transcriptional regulator able to bind singlestranded DNA (ssDNA) and RNA (17) (18) (19) , as a potential RUNX1-regulator. FUBP1 promotes cell proliferation, inhibits apoptosis, and enhances cell migration by modulating expression of transcripts such as c-MYC (MYC), P21 (CDKN1A) and Noxa (Pmaip1) (18, (20) (21) (22) (23) . FUBP1 is also implicated in different processes in RNA regulation such as post-transcriptional regulation or splicing (19, (24) (25) (26) (27) . Accordingly, FUBP1 endorses both oncogenic and tumor suppressor roles (21, 22, (28) (29) (30) (31) . Importantly, FUBP1 has been recently described as an important regulator of the expansion and self-renewal of hematopoietic stem cells (20, 32, 33) . Potential cancer driving mutations of FUBP1 have also been reported in chronic and acute pre-B lymphocytic leukemias (34) (35) (36) .
In this context, we hypothesized that FUBP1 could functionally cooperate with RUNX1. We demonstrate that the oncogene c-KIT (KIT) is one of FUBP1 and RUNX1 common target genes. We characterized two regulatory regions at +700 pb and +30 kb from Transcription Start Site (TSS) within the first intron of c-KIT which are bound by RUNX1 and FUBP1, together with active histone marks. c-KIT is a crucial player in hematopoietic stem cell maintenance and differentiation (37, 38) and presents oncogenic functions (39, 40) . We uncovered here that upregulation of c-KIT by FUBP1 and RUNX1 impacts cell proliferation, which can be counteracted by the pharmacological c-KIT inhibitor, imatinib mesylate. Altogether, our data underscore a novel mechanism of regulation of the oncogene c-KIT that could play a role in pathophysiological context of RUNX1 and FUBP1 deregulation.
MATERIALS AND METHODS
Detailed experimental procedures for RNA extraction, RT-qPCR, generation of stable cell lines, coimmunoprecipitation, cells sorting, immunoblotting, chromatin immunoprecipitation (ChIP-Seq), luciferase assay, molecular simulation, immunophenotyping, and cell proliferation assays are included in supplemental materials and methods. Lists of primary antibodies and primers are outlined in Supplementary Tables S1 and S2 .
Cell lines and patients' cells
Pre-B leukemia cell line Nalm6 (ATCC® CRL-3273™) was maintained in RPMI-1640 medium containing 10% heat-inactivated fetal calf serum (FCS) and 1% antibiotics (penicillin/streptomycin). HEK293 cells (ATCC ® CRL-1573™) were maintained in DMEM/10% FCS/1% antibiotics. Bone marrow cells from pre-B acute lymphoblastic leukemia patients were collected at diagnosis, after informed consent had been obtained, in accordance with the declaration of Helsinki. The protocol was approved by the ethics committee of Rennes Hospital (France).
Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) RIME was conducted with Nalm6 cells as previously described (41) . The lysates were incubated with two anti-RUNX1 and normal rabbit IgG antibodies (Supplementary Table S1 ). Peptides were visualized using Scaffold 4 software (http://www.proteomesoftware.com/products/ scaffold/). We selected proteins where the sum of peptide count for both RUNX1 antibodies is at least three and higher than 2-fold IgG background. Proteins identified by only one RUNX1 antibody were excluded.
Proximity ligation assay (PLA)
PLA was carried out with Duolink ® In Situ Detection Reagents and Probes (DUO92007, DUO92002 and DUO92004, Sigma-Aldrich). The protocol was described in Debaize et al. (42) . Quantification of PLA dots per nucleus was performed by automatic counting with ImageJ and values below the assay cut-off (set to two standard deviations over background signal) were considered negative for the interaction of interest (42) .
Generation of stable cell lines
We used the constructs pLKO1-shFUBP1 (TRCN0000230197, Sigma Aldrich), pLenti-CMV-Puro-DEST-Flag-FUBP1, pLenti-CMV-Puro-DEST-Halotag-RUNX1 (from pFN21A #FHC01784, Kazusa collection, Promega), pSPAX2 (a gift from Didier Trono, Addgene plasmid #12260) and pCMV-VSV-G (a gift from Bob Weinberg, Addgene plasmid #8454) (43) to produce lentivirus to generate HEK293 shFUBP1 , Nalm6 +FUBP1 and Nalm6 +RUNX1 Nalm6 +RUNX1+FUBP1 stable cell lines. Transfected cells were selected with 1.1 or 0.25 g/ml puromycin (44) . pLenti-CMV-Puro-DEST was a gift from Eric Campeau (Addgene plasmid #17452) (45) . For details, see the supplemental Methods.
Chromatin immunoprecipitation (ChIP) and binding site analysis
The procedure was adapted from a previous study (46) . Detailed procedure is described in the supplemental methods. All sequencing data are available at NCBI GEO ( GSE109377). Genomic regions were analyzed with CEAS (47) and GREAT (48) software to uncover enriched genomic regions.
Luciferase assay
Genomic DNA fragments derived from the human c-KIT gene and control DNA were cloned into pGL4.10-luc with a minimal promoter and transfected in HEK293 shFUBP1 cells, in presence of pFN-Halotag-RUNX1 (#FHC01784, Kazusa collection, Promega) and/or pCDNA-Flag-FUBP1 and supplemented with empty pCDNA vector. For luciferase assays in Nalm6 cells, the +30 kb enhancer region was cloned with the minimal promoter into a MSCV Luciferase PGK-hygro vector (a gift from Scott Lowe, Addgene plasmid #18782) by the Gibson Assembly ® Cloning Kit (NEB). To produce the +30 kb enhancer-MSCV-luciferase retrovirus, HEK293 cells were co-transfected with +30 kb enhancer-MSCV-luciferase together with pCMV-VSV-G and pGag-pol (49) . Nalm6 transduced cells were selected with 300 g/mL hygromycin. FUBP1 truncated expression vector (FUBP1 del-CEN ) was kindly provided by W. Keith Miskimins (50) . Mutated RUNX1 (RUNX1 R174Q , RUNX1
R174Q-T161A ) expression vectors were generated by site-directed mutagenesis.
Molecular simulation
Models of the KH3 FUBP1 subdomain complexed to single-stranded DNA were based on the nuclear magnetic resonance (NMR) solution structure 1J4W from the Protein Data Bank. YASARA software (http://www.yasara. org), Amber03 force field and standard protocols (51) were used to produce binding energies.
Immunophenotyping
Intracellular and surface stainings of c-KIT protein were performed by flow cytometry using APC-Mouse-AntiHuman CD117 antibody (Clone YB5.B8, BD Biosciences).
Cell proliferation and cell analysis
Proliferation assays were done by automatic counting with a Cellometer (Nexcelom). Apoptosis/necrosis analyses and inhibition assays were performed with automatic counting following Hoechst, propidium iodine and Yo-Pro stainings.
Xenograft transplantation and survival analysis
NOD/scid IL2 Rg null mice (Charles River Laboratories, France) were maintained in the ARCHE Animal Housing Center (Rennes, France). Animal experiments were performed after authorization by the French Research Ministry, and according to European regulation. Four-weekold mice received two intraperitoneal injections of 20 g/g busulfan (60 mg/10 ml, Pierre Fabre) on 2 days. They were then allowed to rest for 2 days before intravenous retroorbital injection of 100 000 cells as previously described (44) .
RESULTS

RUNX1 ChIP-Seq signal is enriched within transcriptionally active chromatin regions in pre-B cells
To investigate the transcriptional role of RUNX1 in human pre-B cells, we mapped its genome-wide distribution by chromatin immunoprecipitation followed by sequencing (ChIP-Seq) in pre-B Nalm6 cells and bone marrow cells isolated from pre-B leukemic patients. Antibody against RUNX1 was validated in our models ( Supplementary Figure S1A and B) . To correlate RUNX1 engagement with chromatin activity in Nalm6 cells, we ran ChIP-Seq of histones H3K4me1, H3K4me3 and H3K27ac, respectively markers of active/poised enhancers, active/poised promoters and active promoters/enhancers.
Replicates of RUNX1 ChIP-Seq in Nalm6 cells retrieved 5514 common peaks, 69% (3803 peaks) of which are also found in RUNX1 ChIP-Seq peaks in at least two out of three pre-B leukemic patients ( Figure 1A ). Those 3803 peaks were assigned to 2651 genes (Supplementary Table  S3 ). RUNX1-bound regions were highly enriched in promoters (-1 kb from the TSS) and in 5 UTR regions (Figure 1B) . RUNX1-bound regions were associated with enriched H3K4me3 and H3K27ac signals in promoters, and with H3K4me1 and H3K27ac signals in genomic regions excluding promoters (no-promoter regions) ( Figure 1C ). Finally, the average RUNX1 signal peaked at regions positive for H3K4me3, H3K4me1 and H3K27ac but not at random regions ( Figure 1D ). Ontology analyses of these genes reveal an enrichment in biological processes related to transcription regulation, cell cycle regulation and a variety of hematologic processes ( Figure 1E and Supplementary Table S4). Cancer, cardiovascular disease, and hematopoietic disease are also enriched in disease ontology analysis (Figure 1E and Supplementary Table S4) . Altogether, our data show that RUNX1 localizes on chromatin in transcriptionally active chromatin regions mainly in promoter and enhancer regions in human pre-B cells.
FUBP1 protein interacts with RUNX1 in hematopoietic lineages
To identify RUNX1 co-factors able to modulate its transcription activity, we performed immunoprecipitations of endogenous RUNX1 protein in pre-B Nalm6 cells with two different antibodies followed by mass spectrometry (RIME) (41) (Figure 2A ). We identified 20 RUNX1-associated proteins (Supplementary Table S5 ). RUNX1 was recovered with the highest number of peptides (18-21 peptides). CBFB, a well-known transcriptional cooperating factor responsible for RUNX1 stabilization on chromatin (14) , was also recovered with 3-4 peptides. Together, these results validated the RUNX1-RIME approach. Interestingly, 9-14 peptides from the Far Upstream Element Binding Protein 1 (FUBP1) were identified, although FUBP1 peptides were also enriched with control IgGs but to a lower extent (Figure 2A) . Given that RUNX1 and FUBP1 share common roles in hematopoietic lineages, a potential functional interaction between these two proteins was further investigated.
We confirmed the RIME-based results using a targeted approach. Flag-tagged FUBP1 and Halotag-tagged RUNX1 were co-expressed in HEK293 cells. We found that Halotag-RUNX1 co-immunoprecipitated with Flag-FUBP1 using an anti-Flag antibody ( Figure 2B ) and conversely, Flag-FUBP1 co-immunoprecipitated with Halotag-RUNX1 using an anti-Halotag antibody (Supplementary Figure S1C ). We then interrogated whether (81) for biological process and GREAT (48) for disease ontology were shown. We selected 5 non-redundant annotations among the 10 most significant. RUNX1 and FUBP1 colocalize under physiological conditions in human pre-B cells. To that aim, we used the Proximity Ligation Assay (PLA), which is a powerful technique to detect endogenous protein-protein spatial proximity ( Figure 2C and D) (42) . As expected (13, 14) , PLA dots were observed with RUNX1 and CBFB proteins in Nalm6 cells, thereby validating the approach. Importantly, we detected a close proximity between RUNX1 and FUBP1 proteins in the nuclear compartment ( Figure 2C ) in accordance with their transcriptional function (52, 53) .
Interestingly, we also detected a close molecular proximity between FUBP1 and CBFB proteins, suggesting that RUNX1, FUBP1 and CBFB associate in one or several regulatory complexes. The absence of any detectable PLA signal between FUBP1 and other transcription factors (TFAP4, USF1) strengthened the specificity of the interactions observed between FUBP1, RUNX1 and CBFB ( Figure 2C ). Additional PLA analyses in Nalm6 cells demonstrated that FUBP1 is in close molecular proximity with CBP and P300, two transcriptional co-activators known to be part of RUNX1 complexes (54) ( Figure 2C ) suggesting that FUBP1 and RUNX1 can colocalize in a same transcriptional complex. Importantly, the proximity between FUBP1, RUNX1 and CBFB were confirmed in bone marrow cells from all three tested pre-B leukemic patients ( Figure 2D ). Finally, comparable results for FUBP1 and RUNX1 proximity were obtained in other pre-B cell lines (BJAB and REH cells) (Supplementary Figure   S1D) . Interestingly, we demonstrated a proximity between FUBP1 and the fusion protein ETV6-RUNX1 in REH cells (Supplementary Figure S1D) . Moreover, we evidenced a spatial proximity between FUBP1 and RUNX1 in human CD34+ hematopoietic stem and progenitor cells (Supplementary Figure S1E ). Altogether, these data indicate that FUBP1 is likely to influence RUNX1 transcriptional activity in blood cells. Figure 3A, Supplementary Figure S2A) . Interestingly, enforced expression of FUBP1 (in Nalm6 +FUBP1 ) strongly upregulated c-KIT expression with an opposite profile upon depletion of FUBP1, suggesting that RUNX1 and FUBP1 could participate in c-KIT transcription ( Figure 3A, Supplementary Figure S2A and B) .
Nucleic Acids
We then analyzed ChIP-Seq data for RUNX1 and histones marks along the c-KIT gene in pre-B Nalm6 and bone marrow cells from leukemic patients. We identified two strong RUNX1 binding regions in the first intron of c-KIT: one at +700 bp and another one at +30 kb from TSS, that overlapped respectively with H3K4me3 and H3K4me1 marks and displayed H3K27ac marks, indicating active chromatin regions ( Figure 3B ).
To investigate the binding of FUBP1 on those two chromatin regions, FUBP1 antibody was first validated for IP in HEK293 +FUBP1 (Supplementary Figure S2C) and tested for ChIP-qPCR on CDKN1A and MYC loci. Very few target regions, including CDKN1A and MYC loci, are described as bound by FUBP1, with results varying with the models (19, 20, (56) (57) (58) . We found that FUBP1 binds to CDKN1A promoter in Nalm6 control compared to Nalm6 shFUBP1 , but not to the -1.5kb MYC promoter (Supplementary Figure  S2D) . These results validate FUBP1 antibody for ChIP. Bindings of RUNX1 and FUBP1 to both c-KIT intronic regions were validated by ChIP-qPCR and showed higher fold enrichment at the +30 kb enhancer compared to the +700 bp site ( Figure 3C) . Importantly, the +30 kb enhancer conferred an additive responsiveness to transcription activation upon RUNX1 and FUBP1 transfection in luciferase reporter assays performed in HEK293 shFUBP1 cells (Figure 3D) , in which endogenous FUBP1 was depleted (Supplementary Figure S2E ). Conversely, the promoter region (+700 bp) mostly responded to RUNX1 expression (Figure 3D) . We therefore focused on the +30 kb enhancer region (500-nucleotide-long). Stable RUNX1 or FUBP1 overexpression in Nalm6 cells demonstrated the responsiveness of the +30 kb enhancer of c-KIT to transcription activation upon RUNX1 or FUBP1 expression. Moreover, the combination of RUNX1 and FUBP1 shows synergetic effect on the c-KIT +30 kb enhancer ( Figure 3E ). Altogether, these data demonstrate that the c-KIT enhancer at +30 kb is controlled by RUNX1, FUBP1 and more importantly RUNX1 together with FUBP1 in pre-B lymphoblasts, suggesting a cooperativity between those two transcription regulators.
RUNX1 and FUBP1 cooperate for the regulation of the +30 kb enhancer of c-KIT
To address the question of the cooperativity between RUNX1 and FUBP1 for the regulation of c-KIT expression ( Figure 4A ), we conducted RUNX1 ChIP-qPCR on +30 kb enhancer upon presence (in Nalm6 control ) or depletion of FUBP1 (in Nalm6 shFUBP1 ). We showed that there is ∼4.5-fold more RUNX1 bound to the +30 kb enhancer in presence of FUBP1 than upon depletion of FUBP1.
We next investigated the impact of RUNX1 and FUBP1 modulation on histones marks at the promoter and the enhancer. We showed that enforced expression of RUNX1, FUBP1 or both RUNX1 with FUBP1 increases H3K4me1 and H3K27ac signal at the +30 kb enhancer, and H3K4me3 and H3K27ac at the promoter ( Figure 4B) . Importantly, the strong increase of H3K27ac signal when both RUNX1 and FUBP1 are overexpressed indicates a strong activation of the gene transcription ( Figure 4B ). Those data demonstrate that RUNX1 and FUBP1 cooperate at the +30 kb c-KIT enhancer and modulate the chromatin state at this region.
Identification of RUNX1 and FUBP1 DNA binding motifs within the +30 kb enhancer of c-KIT
Analysis of the +30 kb c-KIT enhancer (500-nucleotidelong) revealed the presence a 29-nucleotide-long FUSElike sequence homologous to the sole FUBP1-binding motif described so far and called the FUSE sequence (18,59) ( Figure 5A ). We also predicted two RUNX1 binding sites that displayed high sequence conservation with the RUNX1 consensus motif 5 -TGTGGT-3 (60,61). To investigate the importance of these sequences in RUNX1-and FUBP1-dependent transcriptional activation, we mutated RUNX1-and FUBP1-predicted binding sites in +30 kb enhancer luciferase reporter vector. Mutations of those predicted binding sequences resulted in the abrogation of the effects of RUNX1 and FUBP1, indicating that identified RUNX1-and FUBP1 FUSE-like binding sites are functional and that each element is required for the transcriptional activation of the +30 kb enhancer of c-KIT ( Figure 5B) .
Additionally, DNA-binding mutants of RUNX1 protein (RUNX1 R174Q and RUNX1 T161A,R174Q ) (62,63) and truncation of FUBP1 central DNA-binding domain encompassing four K-Homology (KH) subdomains (50) reduced the transcription activity of the +30kb enhancer in luciferase reporter assays ( Figure 5C ). Those results demonstrated that RUNX1-and FUBP1-DNA-binding domains are necessary for a maximal transcriptional activation of the +30 kb enhancer of c-KIT.
Since FUBP1 requires two functional subdomains (KH3 and KH4) to bind DNA (18, 59, 64, 65) (Figure 5A ), and because FUBP1-DNA binding sequences are documented only for a few genes (19, 64) , we investigated the binding energies of the KH3 and KH4 subdomains on the +30 kb c-KIT enhancer ( Figure 5D ). We generated 12 structural models of KH3 binding to single-stranded-DNA sliding sequences in 3 from the theoretical positioning of the KH4 subdomain on the 5 -TATTCC-3 sequence. A maximal binding energy was measured for the AT-rich sequence 5 -ATATAAA-3 located in 3 at 7-nucleotide-apart from the KH4-bound sequence. This novel KH3-bound sequence is coherent with the previously described AU-rich FUBP1 RNA-bound sequence (66) and its position relative to the KH4-bound motif is fully consistent with the inter-domain distance suggested by previous structural studies (59) . The structural model of KH3 binding to 5 -ATATAAA-3 se- Figure S2A ) and expression data are given compared to Nalm6 control cells after normalizing with GAPDH mRNA (error bars are S.D.). *P < 0.05, **P < 0.01, ***P < 0.001 in Mann-Whitney tests. (B) Genomic tracks displayed ChIP-Seq data for RUNX1 and the histones H3K4me3, H3K27ac and H3K4me1 from Nalm6 cells (2 replicates) and bone marrow mononuclear cells isolated from three pre-B acute lymphoblastic leukemia patient across the first 35 kb of the human c-KIT gene (NM 000222). ChIP-Seq data were acquired by Illumina sequencing and visualized with Integrated Genome Browser 9.0.0 (82). ChIP-Seq reads were aligned to the reference human genome version GRCh37 (hg19). Both genomic regions of c-KIT gene that were associated with active histone marks are located within the first intron, one in a promoter region (+700 pb from TSS) and the another in an enhancer region (+30 kb from TSS) and are indicated by boxes. (C) ChIP-qPCR performed on samples from Nalm6 cells using a specific anti-RUNX1 (n = 3), anti-FUBP1 (n = 3) or a non-specific control IgG. ChIP-qPCR shows fold enrichment for c-KIT promoter (+700 pb) and enhancer (+30 kb) regulatory regions. Figure S2E ). Note that the HEK293 shFUBP1 cells do not express RUNX1 and that the FUBP1 expression vector is resistant to shFUBP1. Luciferase levels (firefly luciferase/Renilla luciferase) are represented using a scatter dot plot indicating the means and S.D. of at least 4 independent experiments. NS: non-significant, * < 0.05 in Mann-Whitney tests. (E) Luciferase assays with a vector containing the c-KIT enhancer regions downstream a minimal promoter and a luciferase ORF, in presence of RUNX1 and FUBP1 expressing vectors in Nalm6 control , Nalm6 +RUNX1 , Nalm6 +FUBP1 and Nalm6 +RUNX1+FUBP1 cells. Luciferase levels are represented using a scatter dot plot indicating the means and S.D. of at least four independent experiments (i.e. each dot represents an independent stable cell line). The expression level of RUNX1 is similar in Nalm6 +RUNX1 and Nalm6 +RUNX1+FUBP1 . The expression level of FUBP1 is similar in Nalm6 +FUBP1 and Nalm6 +RUNX1+FUBP1 (refer to Figure 6A, Supplementary Figure S3B) . NS: non-significant, *P < 0.05 in Mann-Whitney tests. quence indicates that stabilization of this complex is mainly driven through hydrophobic contacts with the ssDNA nucleobases and electrostatic interactions with the ssDNA sugar phosphate backbone of amino-acids located in a groove ( Figure 5D ).
Hence, we have identified the RUNX1 binding sequences and a new FUBP1 FUSE-like binding sequence, where KH4 and KH3 FUBP1-subdomains bind on the intronic enhancer of c-KIT, which functionally regulate c-KIT expression.
FUBP1 and RUNX1 exacerbate the c-KIT pathway and contribute to cell proliferation
To further investigate the cooperative role of FUBP1 and RUNX1 in c-KIT regulation, we compared c-KIT level and functionality in pre-B Nalm6 cells overexpressing FUBP1 and/or RUNX1. c-KIT transcript levels were elevated in Nalm6 +RUNX1 , Nalm6 +FUBP1 and in Nalm6 +RUNX1+FUBP1 stable cell lines ( Figure 6A ). Furthermore, we identified a positive correlation between FUBP1 and c-KIT mRNA levels as well as between RUNX1 and c-KIT mRNAs (Figure 6B) . Comparable results were obtained in REH cells and ETV6-RUNX1 leukemia patient biopsies (data from St. Jude Children's Research Hospital--Pediatric Cancer Data Portal) (67) (Supplementary Figure S3A) . Importantly, the presence of RUNX1 reinforces the regulation of c-KIT by FUBP1 ( Figure 6B ). The c-KIT protein steadystate levels were also elevated (Supplementary Figure S3B) . This phenotype was more pronounced for both intracellular and surface c-KIT in Nalm6 cells overexpressing FUBP1 or FUBP1+RUNX1 as shown by FACS ( Figure  6C ). Upon binding of the c-KIT ligand, the Stem Cell Factor (SCF), c-KIT dimerizes and autophosphorylates allowing the activation of its downstream pathways, including the ERK MAP-kinase pathway (68) . Hence, to investigate the functionality of c-KIT, we next analyzed phospho-c-KIT in Nalm6 control and Nalm6 +FUBP1 cells treated with SCF. Nalm6 +FUBP1 cells showed a faster response to SCF than control cells with higher levels of phospho-c-KIT and phospho-ERK1/2 after 5 minutes of treatment (Supplementary Figure S3C ). In addition, SCF induces c-KIT internalization and degradation, one of the hallmarks of c-KIT functionality (69) . Following SCF stimulation, c-KIT was more intensively internalized in Nalm6 +FUBP1 and especially in Nalm6 +RUNX1+FUBP1 than in Nalm6 control cells. These results suggest that a stronger biological response to SCF is elicited by overexpressing RUNX1 and FUBP1 (Figure 6D) .
Having demonstrated that FUBP1 and RUNX1 regulate c-KIT and that c-KIT is properly functional, we next addressed the question of the physiological consequence of this regulation. Nalm6 +FUBP1 , Nalm6 +RUNX1 and Nalm6 +RUNX1+FUBP1 cells presented a higher proliferation rate than Nalm6 control cells ( Figure 7A ). This result was consistent with the proliferation arrest induced by FUBP1 loss-of-function (32, 70) . The gain-in-proliferation phenotype was slightly exacerbated in presence of SCF ( Figure  7A ) as anticipated from the surface membrane c-KIT inter- Figure  S3D) . A BrdU pulse-chase assay allowed us to correlate this increase in proliferation rate to an acceleration of cell cycle in Nalm6 +FUBP1 , Nalm6 +RUNX1 and Nalm6 +RUNX1+FUBP1 cells compared to Nalm6 control cells ( Supplementary Figure S3E) . Finally, mice xenografted with Nalm6 +FUBP1 , Nalm6 +RUNX1 or Nalm6 +RUNX1+FUBP1 cells presented a reduced survival compared to mice injected with Nalm6 control cells ( Figure 7B ). Altogether, these data demonstrate that enforced expression of FUBP1 and RUNX1 regulate c-KIT expression and subsequent cell proliferation.
We next evaluated Nalm6 cells responsiveness to a c-KIT inhibitor, the imatinib mesylate (71) . While Nalm6 control , Nalm6 +FUBP1 , Nalm6 +RUNX1 and Nalm6 +RUNX1+FUBP1 cells were sensitive to imatinib mesylate at a standard concentration of 1 M as shown by the decreased phosphorylation of c-KIT and of downstream targets such as ERK and AKT (Supplementary Figure S3F) , cells overexpressing FUBP1, RUNX1, alone or together, were less sensitive to the inhibitor in a proliferation assay beyond the dose of 1 M ( Figure 7C ). This result demonstrates that FUBP1 and RUNX1 levels can impact on the sensitivity of the cells to a c-KIT inhibitor.
DISCUSSION
In our search for identifying transcriptional co-factors of RUNX1 and deciphering its function, we demonstrated that RUNX1 and FUBP1 co-immunoprecipitated and are physically located close to each other on active chromatin of human hematopoietic cells.
Examination of RUNX1 genome-wide distribution together with gene expression data led us to propose that the oncogene c-KIT is commonly activated by RUNX1 and FUBP1. Moreover, we identified two regulatory regions in the first intron of c-KIT (the +700 bp promoter and the +30 kb enhancer regions) that are bound by RUNX1, FUBP1 and present active histone marks. Interestingly, a very recent study in AML1-ETO acute myeloid leukemia spotted identical regulatory regions in c-KIT gene bound by RUNX1 (or AML1) and the fusion protein AML1-ETO (72) . The role of the transcriptional regulators RUNX1 and FUBP1 in a potential interplay between c-KIT enhancer and promoter has not been addressed yet. However, Tian et al. identified a DNA-loop between the promoter and the +30 kb enhancer of c-KIT that plays a significant role in transcriptional regulation (72) . Since FUBP1 induces a similar promoter-enhancer loop in the c-MYC gene through interaction with TFIIH (73), we propose that FUBP1 could trigger the formation of such a DNA-loop at the c-KIT locus.
Optimal FUBP1 binding sequences are still a matter of debate (19, 22, 59, 64, 74) . Here, we benefit from the functional c-KIT enhancer to bring new insights on novel FUBP1 DNA-binding sequences. Analysis of the +30 kb c-KIT enhancer, by molecular biology and structural modeling, allows us to report a c-KIT FUSE-like sequence encompassing the KH4 binding sequence (retrieved from the c-MYC promoter (18, 59) ), a 7-nucleotide-long spacer that may not interact with FUBP1 as described previously (59), and an AT-rich sequence bound by the KH3 subdomain consistently with FUBP1-bound AU-rich sequences described previously (66) .
c-KIT encodes a tyrosine kinase receptor and is expressed in hematopoietic stem and progenitor cells (38, 75) . Binding of SCF to the c-KIT receptor triggers a cascade of signaling pathways resulting in the regulation of apoptosis, proliferation and differentiation (68) . Inappropriate c-KIT expression bears oncogenic consequences. c-KIT gene is found overexpressed in human leukemia from myeloid and some lymphoid lineages (67, 68, 76, 77) and constitutive c-KIT activity triggers lymphoblastic leukemia in mouse model (78) . Our findings suggest a new mechanism for the control of cell proliferation via the fine-tuned regulation of c-KIT by FUBP1 and to a lesser extent RUNX1. Importantly, we demonstrated that FUBP1-induced c-KIT expression produces a functional protein with increased tyrosine phosphorylation of its substrates and faster internalization following SCF stimulation. The phenotype on proliferation associated to c-KIT pathway activation is reinforced when both FUBP1 and RUNX1 are overexpressed. , and RUNX1 in Nalm6 control , Nalm6 +RUNX1 , Nalm6 +FUBP1 , and Nalm6 +RUNX1+FUBP1 cells. Results are presented in terms of a fold change after normalizing with GAPDH mRNA. Each dot represents a biological replicate. NS: non-significant, **P < 0.01, ***P < 0.001, ****P < 0.0001 in Mann-Whitney tests. (B) Correlation between FUBP1 and KIT mRNA levels from different transduced Nalm6 +FUBP1 and Nalm6 +RUNX1+FUBP1 stable cell lines, and correlation between RUNX1 and KIT mRNA levels in Nalm6 +RUNX1 and Nalm6 +RUNX1+FUBP1 cells are presented. P-value (p), Pearson correlation coefficient (r), slope of the correlation curve (slope), and number of biological replicates analyzed (n) are indicated. (C) FACS analyses following c-KIT (CD117) intracellular and surface staining in Nalm6 control , Nalm6 +RUNX1 , Nalm6 +FUBP1 , or Nalm6 +RUNX1+FUBP1 cells. The c-KIT expression was assessed in comparison with the control isotype staining. A representative analysis of the KIT surface staining is shown on the left. Percentage of the mean fluorescence intensity (MFI) is presented on the right panel (n = 4-8 per group) after normalizing with Nalm6 control cells. Statistical significance was assessed compared to Nalm6 control cells by MannWhitney tests (NS: non-significant, *P < 0.05, **P < 0.01, ***P < 0 .001). (D) Mean fluorescence intensity (MFI) analyzed by FACS from Nalm6 control , Nalm6 +RUNX1 , Nalm6 +FUBP1 , and Nalm6 +RUNX1+FUBP1 cells following SCF treatment (0 or 100 ng/ml of SCF were added in the culture media and incubated 5 min at 37 • C) and c-KIT surface staining. SCF induces c-KIT internalization and degradation, one of the hallmarks of c-KIT functionality (69) . Statistical significance was assessed compared to untreated cells (without SCF) by Mann-Whitney tests (NS: non-significant, *P < 0.05, **P < 0.01, ***P < 0 .001).
cell-enriched cell populations and in some lymphoblastic leukemia subtypes (data from St. Jude Children's Research Hospital) (67, 79) as well as RUNX1 (80) . Here, we proposed for the first time a rationale for oncogenic function of FUBP1 in leukemia. Therefore, since RUNX1, FUBP1 and c-KIT are overexpressed in some subtypes of leukemia, abnormalities in this regulatory network could participate in the onset or the maintenance of RUNX1-related leukemia. We hypothesize that the c-KIT pathway may be impaired in those models and draw attention to the possible decrease in sensitivity under c-KIT inhibitor treatment.
In conclusion, we demonstrate a regulatory network involving two transcriptional regulators, RUNX1 and FUBP1, in the control of the +30 kb c-KIT enhancer. FUBP1 and RUNX1 colocalize on active chromatin, cooperate for regulating c-KIT transcription, and promote cell cycle progression. Although our study focuses on the role of the cooperativity between RUNX1 and FUBP1 in the regulation of c-KIT, we can envision that this partnership most likely impacts on other target genes. Deregulation of this regulatory mechanism may explain some oncogenic function of RUNX1 and FUBP1.
Nucleic Acids Research, 2018, Vol. 46, No. 21 11225 Figure 7 . FUBP1 and RUNX1 contribute to c-KIT-dependent cell proliferation. (A) Proliferation curves from Nalm6 control (n = 5), Nalm6 +RUNX1 (n = 4), Nalm6 +FUBP1 (n = 5), Nalm6 +RUNX1+FUBP1 (n = 5) cells exposed to 0 or 100 ng/ml of SCF the first day (day 0). Histogram (on the right) represents the number (means with S.D.) of cells at day 7. Statistical significance was assessed compared to Nalm6 control by Mann-Whitney tests (NS: non-significant, *P < 0.05, **P < 0.01). (B) Survival curves from immunodeficient NOD/scid IL2 Rg null mice xenografted with 100 000 cells: Nalm6 control , Nalm6 +RUNX1 , Nalm6 +FUBP1 , or Nalm6 +RUNX1+FUBP1 human cell lines (n = 5-10 per group). The general condition of mice was monitored daily until experiment ended. Kaplan-Meier survival curves were plotted. P-value was assessed with Mantel-Cox tests compared to mice xenografted with Nalm6 control . (C) Inhibition curves from Nalm6 control , Nalm6 +RUNX1 , Nalm6 +FUBP1 , and Nalm6 +RUNX1+FUBP1 cell lines treated with 100 ng/ml of SCF and with growing concentrations of imatinib mesylate (0-10 M) for 48h. Each point is the mean of four biological replicates ± S.E.M. Statistical significance was assessed at 10 M compared to Nalm6 control by Mann-Whitney tests (*P < 0.05).
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